ClinicalTrials.gg
Not yet recruitingNCT07826195Updated Sep 17, 2026

A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors

A Phase 2 interventional study of Injectable ALK-N001 in Advanced Gastrointestinal Tumors, sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This open-label, multicenter Phase IIa study is to evaluate the efficacy and safety of injectable ALK-N001 in patients with advanced gastrointestinal tumors, with the primary objective to assess its preliminary efficacy.

02

Conditions studied

  • Advanced Gastrointestinal Tumors

Keywords

  • ALK-N001
  • Advanced Gastrointestinal Tumors
  • Phase IIa
03

In context

Lead sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign , understand the study and be willing and able to comply with all study procedures.
  2. Age ≥18 years (male or female) at the time of signing informed consent.
  3. or cytologically confirmed locally advanced or esophageal squamous cell carcinoma, colorectal adenocarcinoma, or other gastrointestinal tumors.
  4. Disease progression or intolerance after prior standard-of-care (SoC) treatment:

    1. Cohort1 (ESCC): Not eligible for curative surgery/radiochemotherapy; progressed or intolerant after at least platinum-based chemotherapy plus PD-(L)1 inhibitor. If immunotherapy is declined/ineligible, progressed after ≥2 lines of systemic therapy.
    2. Cohort2 (CRC): Received standard systemic therapy for metastatic colorectal cancer and experienced progression or intolerance. Must have received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy (±bevacizumab/cetuximab), unless . For MSI-H/dMMR tumors, prior PD-(L)1 inhibitor is required.
    3. Cohort3 (Other GI tumors): Not curable by surgery; disease progression/intolerance after standard-of-care therapy, or no available effective treatment.
  5. At least one per V1.1 (lesions in prior radiation field generally not measurable unless clear progression).
  6. performance status 0 or 1.
  7. Expected survival ≥3 months.
  8. Adequate organ function:

    • Bone marrow (no transfusion/growth factors within prior 14 days): ≥1.5×10⁹/L; ≥90×10⁹/L; ≥90 g/L
    • Liver: ≤1.5×; ≤3×ULN (≤5×ULN for liver metastasis); AST ≤3×ULN (≤5×ULN for liver metastasis); ALB ≥35 g/L
    • Renal: Cr ≤1.5×ULN; if Cr>1.5×ULN, ≥50 mL/min (Cockcroft-Gault formula)
    • Coagulation: ≤1.5×ULN; INR ≤1.5×ULN
  9. Women of must have negative pregnancy test at screening and agree to effective or abstinence from consent until 6 months after last dose. Male participants must use effective contraception or abstinence from consent until 6 months after last dose; no sperm donation.

Exclusion criteria

Exclusion Criteria:

  • 1. Received chemotherapy, radiotherapy (palliative local radiotherapy within prior 2 weeks), biotherapy, targeted therapy, immunotherapy, TIL or other anti-tumor therapies within 4 weeks before first dose.

    1. Anti-endocrine therapy within 2 weeks or 5 half-lives; oral CDK4/6i, small molecule targeted agents, anti-tumor Chinese medicine.
    2. CAR-T, CAR-NK or tumor vaccine within prior 3 months.
    3. within 2 weeks; non-live vaccine within 4 weeks before first dose.
    4. drug within 4 weeks or 5 half-lives before first dose (whichever shorter).

      2. Use of strong inducer/inhibitor within 7 days before first dose or planned during study.

      3. Prior treatment with DXD-containing ADC or PDC. 4. Active infection at screening requiring systemic anti-infective therapy within 2 weeks prior to first dose.

      5. Known BRAF mutation or NTRK fusion positive colorectal cancer (Cohort2). 6. Unstable or progressive CNS/ (stable ≥1 month, no new/enlarging lesions and off ≥4 weeks may enroll).

      7. Clinically uncontrolled third-space effusion requiring therapeutic paracentesis/drainage within prior 14 days.

      8. Prior or current interstitial lung disease (ILD), non-infectious pneumonitis requiring steroids, suspected ILD or severely impaired pulmonary function.

      9. Severe GI disease including chronic inflammatory bowel disease, bowel obstruction or chronic diarrhea.

      10. Esophageal stent placement, tracheal stent or esophageal stricture (Cohort1).

      11. Severe cardiovascular disease:

    <!-- -->

    1. cardiac arrhythmias or 2nd/3rd degree AV block requiring intervention.
    2. Acute coronary syndrome, heart failure, stroke or grade ≥3 cardiovascular event within 6 months.
    3. Class ≥II heart failure (exception: stable NYHA II, ≥50%, no exacerbation ≥6 months after optimized medical treatment, confirmed by cardiologist).
    4. Uncontrolled hypertension: SBP≥150 mmHg and/or DBP≥100 mmHg. 12. History of GI perforation/fistula within 6 months before first dose, or tumor invading adjacent organs (great vessel/trachea) with high risk of bleeding/fistula.

      13. History of severe thromboembolism within prior 6 months; known inherited/acquired thrombophilia.

      14. Other within past 5 years (exception: cured cervical carcinoma in situ, cutaneous squamous cell carcinoma, basal cell carcinoma, papillary thyroid carcinoma).

      15. Prior allogeneic hematopoietic stem cell or solid organ transplantation. 16. Prior anti-tumor adverse events not recovered to ≤ Grade1 ( v6.0, alopecia and investigator-assessed non-risk toxicities excluded) or not meeting eligibility lab criteria.

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (ESCC), Dose A (37.5 mg/m²)

    Participants with advanced esophageal squamous cell carcinoma (ESCC) receive injectable ALK-N001 at 37.5 mg/m² intravenously every 2 weeks (Q2W) per 28-day cycle. Enrollment and dose expansion may be adjusted by the Safety Review Committee (SRC) based on accumulated safety, PK, PD and preliminary anti-tumor data. Treatment continues until intolerable toxicity, progressive disease, or other discontinuation criteria.

    Drug: Injectable ALK-N001

  • Experimental
    Cohort 1 (ESCC), Dose B (50 mg/m²)

    Participants with advanced esophageal squamous cell carcinoma (ESCC) receive injectable ALK-N001 at 50 mg/m² intravenously every 2 weeks (Q2W) per 28-day cycle. Enrollment and dose expansion may be adjusted by the Safety Review Committee (SRC) based on accumulated safety, PK, PD and preliminary anti-tumor data. Treatment continues until intolerable toxicity, progressive disease, or other discontinuation criteria.

    Drug: Injectable ALK-N001

  • Experimental
    Cohort 2 (CRC), Dose A (37.5 mg/m²)

    Participants with advanced colorectal carcinoma (CRC) receive injectable ALK-N001 at 37.5 mg/m² intravenously every 2 weeks (Q2W) per 28-day cycle. Enrollment and dose expansion may be adjusted by the Safety Review Committee (SRC) based on accumulated safety, PK, PD and preliminary anti-tumor data. Treatment continues until intolerable toxicity, progressive disease, or other discontinuation criteria.

    Drug: Injectable ALK-N001

  • Experimental
    Cohort 2 (CRC), Dose B (50 mg/m²)

    Participants with advanced colorectal carcinoma (CRC) receive injectable ALK-N001 at 50 mg/m² intravenously every 2 weeks (Q2W) per 28-day cycle. Enrollment and dose expansion may be adjusted by the Safety Review Committee (SRC) based on accumulated safety, PK, PD and preliminary anti-tumor data. Treatment continues until intolerable toxicity, progressive disease, or other discontinuation criteria.

    Drug: Injectable ALK-N001

  • Experimental
    Cohort 3 (Other GI Tumors), Dose A (37.5 mg/m²)

    Participants with advanced other gastrointestinal tumors receive injectable ALK-N001 at 37.5 mg/m² intravenously every 2 weeks (Q2W) per 28-day cycle. Cohort 3 is exploratory and will be activated only if meaningful anti-tumor signals are observed in concurrent ALK-N001 trials. SRC may adjust enrollment based on safety, PK, PD and efficacy data. Treatment continues until intolerable toxicity, progressive disease, or other discontinuation criteria.

    Drug: Injectable ALK-N001

  • Experimental
    Cohort 3 (Other GI Tumors), Dose B (50 mg/m²)

    Participants with advanced other gastrointestinal tumors receive injectable ALK-N001 at 50 mg/m² intravenously every 2 weeks (Q2W) per 28-day cycle. Cohort 3 is exploratory and will be activated only if meaningful anti-tumor signals are observed in concurrent ALK-N001 trials. SRC may adjust enrollment based on safety, PK, PD and efficacy data. Treatment continues until intolerable toxicity, progressive disease, or other discontinuation criteria.

    Drug: Injectable ALK-N001

Interventions

  • DrugInjectable ALK-N001

    Injectable ALK-N001 is administered intravenously every 2 weeks (Q2W; 28-day treatment cycle). Two predefined dose levels are available: 37.5 mg/m² (Dose A) and 50 mg/m² (Dose B). Enrollment or suspension of dose groups may be determined by the Safety Review Committee (SRC) based on safety, PK, PD and preliminary anti-tumor activity data.

    Also known as: QHL-1618

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR), assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR is defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) as evaluated by RECIST V1.1.

    Time frame: Up to approximately 24 months from the first dose.

Secondary outcomes

  1. Duration of Response (DOR)

    Description: DOR is defined as the time from the first documentation of CR/PR until the first documented progressive disease (PD) or death from any cause.

    Time frame: Up to approximately 24 months from the first dose.

  2. Disease Control Rate (DCR)

    DCR is the proportion of participants achieving CR, PR, or stable disease (SD) per RECIST V1.1. Time Frame: Up to approximately 24 months from the first dose.

    Time frame: Up to approximately 24 months from the first dose.

  3. Progression-Free Survival (PFS)

    PFS is the time from study enrollment to documented PD or death from any cause. 6-,12-,24-month PFS rates will be calculated.

    Time frame: Up to approximately 24 months from the first dose.

  4. Overall Survival (OS)

    OS is defined as the time from enrollment to death from any cause. 12-,24-month OS rates will be calculated.

    Time frame: Up to approximately 24 months from the first dose.

  5. Safety (Adverse Events and Serious Adverse Events)

    Incidence, severity and relatedness of AEs and SAEs; laboratory tests, 12-lead ECG, vital signs, physical examination and ECOG performance status.

    Time frame: From informed consent until 28±7 days after last dose.

  6. Population Pharmacokinetics (PopPK) of total DXD and free DXD

    Characterize PopPK profiles of total DXD and free DXD.

    Time frame: From first dose up to end of treatment.

  7. Exposure-Response (E-R) relationship of total DXD and free DXD

    E-R relationship between total/free DXD exposure and efficacy, safety and biomarkers.

    Time frame: From first dose up to approximately 24 months after first dose.

Other outcomes

  1. Expression level of Legumain in tumor tissue

    Tumor tissue samples (fresh biopsy or archived paraffin-embedded tissue) will be collected from all participants at screening (mandatory) and at disease progression (optional) for central laboratory Legumain testing. Previous genetic or protein testing reports will be collected if available. Evaluate the correlation between tumor Legumain expression and anti-tumor efficacy.

    Time frame: Screening (mandatory baseline sample collection); optional sampling at disease progression; analysis up to approximately 24 months after the first dose.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Sep 17, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07826195
Lead sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion